Clinical Spectrum of Levodopa-Induced Complications

被引:211
作者
Aquino, Camila Catherine [1 ]
Fox, Susan H. [1 ]
机构
[1] Univ Toronto, Toronto Western Hosp, Edmond J Safra Program Parkinson Res, Movement Disorder Ctr, Toronto, ON M5S 1A1, Canada
关键词
wearing-off; dyskinesia; dystonia; non-motor fluctuations; phenomenology; PARKINSONS-DISEASE PATIENTS; L-DOPA THERAPY; NONMOTOR FLUCTUATIONS; INDUCED-DYSKINESIAS; ON-OFF; MOTOR FLUCTUATIONS; SUBCUTANEOUS APOMORPHINE; MICTURITION DISTURBANCE; SWALLOWING DYSFUNCTION; RESPIRATORY DYSKINESIA;
D O I
10.1002/mds.26125
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The first years of Parkinson disease (PD) treatment are marked by good and sustained responses to dopaminergic therapy. With disease progression and longer exposure to levodopa (l-dopa), patients develop a range of l-dopa-induced complications that include motor and non-motor symptoms. Motor complications include motor fluctuations, characterized by periods of reduced benefit from the medication, and l-dopa-induced dyskinesia, characterized by emergence of hyperkinetic involuntary movements. Dyskinesia can occur at peak effect of l-dopa, at the beginning and end of dose, or between doses. These motor complications are often associated with fluctuations in non-motor symptoms, particularly fluctuations in neuropsychiatric, autonomic, and sensory symptoms. Recognizing such complications and understanding their relationship with the timing of l-dopa doses is essential for adequate diagnosis and management. (c) 2014 International Parkinson and Movement Disorder Society
引用
收藏
页码:80 / 89
页数:10
相关论文
共 129 条
[1]   Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature [J].
Ahlskog, JE ;
Muenter, MD .
MOVEMENT DISORDERS, 2001, 16 (03) :448-458
[2]  
[Anonymous], 1982, Mov. Disorders
[3]  
[Anonymous], ARCH NEUROL
[4]  
[Anonymous], MOV DISORD
[5]  
[Anonymous], EUR J NEUROL
[6]  
[Anonymous], MOVEMENT DISORDERS
[7]  
[Anonymous], MOV DISORD
[8]   Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies [J].
Bezard, E ;
Brotchie, JM ;
Gross, CE .
NATURE REVIEWS NEUROSCIENCE, 2001, 2 (08) :577-588
[9]  
BLANCHET PJ, 1995, J PHARMACOL EXP THER, V272, P854
[10]   END-OF-DOSE DYSTONIA IN PARKINSONS-DISEASE [J].
BRAVI, D ;
MOURADIAN, MM ;
ROBERTS, JW ;
DAVIS, TL ;
CHASE, TN .
NEUROLOGY, 1993, 43 (10) :2130-2131